IOB - Delayed Quote EUR

Poxel S.A. (0RA2.IL)

0.2995

-0.0035

(-1.16%)

At close: 5:18:13 PM GMT

Poxel Announces its Financial Calendar for 2025

LYON, France, January 23, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2025.

Business Wire 7 days ago

PXXLF
Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

LYON, France, January 21, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that a Combined General Meeting will be held on February 11, 2025, at 9:00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at

Business Wire 9 days ago

PXXLF
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

LYON, France, January 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that China's National Intellectual Property Administration ("CNIPA") has granted Poxel patent ZL201980015603.X for Imeglimin, a first-in-class drug targeting

Business Wire 10 days ago

PXXLF
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

LYON, France, January 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that net sales of TWYMEEG® in Japan reached JPY 5 billion (EUR 30.6 million2) in Sumitomo Pharma's fiscal year 2024, making Poxel eligible for positive net ro

Business Wire 10 days ago

PXXLF
Availability of Poxel’s 2024 Half-Year Financial Report

LYON, France, December 23, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2024.

Business Wire last month

PXXLF
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook

LYON, France, December 09, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces its half-year financial results for the period ended June 30, 2024 and provides an update on its financial situation and outlook, in particular following the

Business Wire last month

PXXLF
Poxel Announces Results from November 28, 2024 Annual General Meeting

LYON, France, November 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that it held its Annual General Meeting on November 28, 2024, at 9;00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cours de Verdun-

Business Wire 2 months ago

PXXLF
Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents

LYON, France, November 07, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that the Annual General Meeting (AGM) will be held on November 28, 2024, at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cour

Business Wire 2 months ago

PXXLF
Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

LYON, France, November 06, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2024.

Business Wire 2 months ago

PXXLF
Poxel Announces Availability of the 2023 Universal Registration Document

LYON, France, October 11, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2023, has been filed with the French market authority (Autorité des Marchés F

Business Wire 3 months ago

PXXLF
Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges

Poxel SA navigates financial restructuring and strategic partnerships amid increased net losses and reduced cash reserves.

GuruFocus.com 3 months ago

POXEL.PA
Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update

LYON, France, October 03, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (MASH2) and rare metabolic disorders, today announced its results for the year ended December 31, 2023, and provided a corporate update.

Business Wire 3 months ago

PXXLF
Poxel Announces its Financial Calendar for 2024

LYON, France, October 01, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.

Business Wire 3 months ago

PXXLF
Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million

LYON, France, September 30, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it entered into a non-dilutive financing agreement with OrbiMed for USD 50 million to monetize a portion of Poxel's future royalties and sales-based payments from TWYMEEG

Business Wire 3 months ago

PXXLF
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update

LYON, France, September 09, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its revenue for the second quarter and first half of 2024.

Business Wire 4 months ago

PXXLF
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

OSAKA, Japan & LYON, France, August 07, 2024--Regulatory News: Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) and POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today topline results obtained from a post-marketing c

Business Wire 5 months ago

PXXLF
Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting

LYON, France, July 15, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today publishes its cash position, provides an update on its financial situation for the second quarter and first half of 2024, ending June 30, 2024, reviews its activities on June 30, 2024 and an

Business Wire 6 months ago

PXXLF
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

LYON, France, May 16, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update.

Business Wire 8 months ago

PXXLF
Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

LYON, France, April 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results re

Business Wire 8 months ago

PXXLF
Poxel to Report Its 2023 Annual Results by the End of April 2024

LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.

Business Wire 9 months ago

PXXLF

Performance Overview

Return	0RA2.IL	CAC 40
YTD	+121.20%	+8.59%
1-Year	-20.71%	+3.94%
3-Year	-92.76%	+14.01%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Poxel S.A. (0RA2.IL)

Poxel Announces its Financial Calendar for 2025

Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

Availability of Poxel’s 2024 Half-Year Financial Report

Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook

Poxel Announces Results from November 28, 2024 Annual General Meeting

Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents

Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

Poxel Announces Availability of the 2023 Universal Registration Document

Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges

Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update

Poxel Announces its Financial Calendar for 2024

Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million

Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

Poxel to Report Its 2023 Annual Results by the End of April 2024

Performance Overview